If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCaledonia Regulatory News (CLDN)

Share Price Information for Caledonia (CLDN)

Share Price is delayed by 15 minutes
Get Live Data
381.00    4.50 (1.20%)
Bid:
378.00
Ask:
383.50
Spread: 5.50 (1.455%)
Market Cap: £1.95b
CLDN Live PriceLast checked at - London Stock Exchange

Intraday Caledonia Share Chart

Director/PDMR Shareholding

31 May 2022 16:50

RNS Number : 4475N
Caledonia Investments PLC
31 May 2022
Β 

Caledonia Investments plc

Notification of transactions of persons discharging managerial responsibilities ("PDMR") or persons closely associated with them ("PCA")

Β 

Pursuant to the requirements of the Market Abuse Regulation, Caledonia Investments plc ("Caledonia" or the "Company") announces that on 30 May 2022 the following nil-cost options over ordinary 5p shares in Caledonia were granted to executive directors under the Caledonia Investments 2020 Performance Share Scheme (the "Performance Share Scheme") and in respect of compulsory deferral of bonus under the Caledonia Investments 2020 Deferred Bonus Plan (the "Deferred Bonus Plan"). The Company's share price used to determine the number of Performance Share Scheme awards and Deferred Bonus Plan awards was 3740p.

Β 

Executive Director

No. of shares over which Performance Share Scheme nil-cost options granted

No. of shares subject to Deferred Bonus Plan

J M B Cayzer-Colvin

14,699

4,666

T J Livett

16,444

5,217

M S D Masters

18,048

3,870

Β 

Subject to the rules of the Performance Share Scheme, nil-cost options are exercisable between three and ten years after the date of grant. Subject to the rules of the Deferred Bonus Plan, deferred share awards vest after a three year retention period.

Β 

The total number of awards held by the above-named executive directors of Caledonia under the Company's performance share schemes and deferred bonus plans following these nil-cost option grants are as follows:

Β 

Executive Director

Total no. of shares held under option under performance share scheme

Total deferred bonus plan share awards

J M B Cayzer-Colvin

91,668

14,716

T J Livett

76,483

10,173

M S D Masters

75,657

13,978

Β 

Further information required by the Market Abuse Regulation in relation to these transactions is set out in the appendix below.

Β 

Enquiries:

Mr R Webster

Company Secretary

Tel: + 44 20 7802 8080

Β 

31 May 2022

Β 

APPENDIX

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

James Michael Beale Cayzer-Colvin

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

Executive Director

b)

Β 

Initial notification /Amendment

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Caledonia Investments plc

b)

Β 

LEI

Β 

2138002FX1MYCA5ZZH32

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Β 

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Ordinary 5p shares

Β 

Β 

GB0001639920

b)

Β 

Nature of the transaction

Β 

Β 

Grant of nil-cost options over ordinary 5p shares under (1) the Caledonia Investments 2020 Performance Share Scheme ("PSS") and (2) the Caledonia Investments 2020 Deferred Bonus Plan ("DBP")

Β 

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Β 

Description

Price(s)

Β 

Volume(s)

Grant of PSS award

Β 

Β£0.00

Β 

14,699

Grant of DBP award

Β 

Β£0.00

4,666

Β 

Β 

d)

Β 

Aggregated information

Β 

- Aggregated volume

Β 

- Price

Β 

Β 

Β 

19,365

Β 

Nil

e)

Β 

Date of the transaction

Β 

30 May 2022

f)

Place of the transaction

Outside a trading venue

Β 

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Timothy James Livett

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

Director/Chief Financial Officer

b)

Β 

Initial notification /Amendment

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Caledonia Investments plc

b)

Β 

LEI

Β 

2138002FX1MYCA5ZZH32

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Β 

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Ordinary 5p shares

Β 

Β 

GB0001639920

b)

Β 

Nature of the transaction

Β 

Β 

Grant of nil-cost options over ordinary 5p shares under (1) the Caledonia Investments 2020 Performance Share Scheme ("PSS") and (2) the Caledonia Investments 2020 Deferred Bonus Plan ("DBP")

Β 

c)

Β 

Price(s) and volume(s)

Β 

Β 

Grant of PSS awards

Β 

Β 

Β 

Β 

Description

Price(s)

Β 

Volume(s)

Grant of PSS award

Β 

Β£0.00

Β 

16,444

Grant of DBP award

Β 

Β£0.00

5,217

Β 

Β 

d)

Β 

Aggregated information

Β 

- Aggregated volume

Β 

- Price

Β 

Β 

Β 

21,661

Β 

Nil

e)

Β 

Date of the transaction

Β 

30 May 2022

f)

Place of the transaction

Outside a trading venue

Β 

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Mathew Simon Dexter Masters

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

Director/Chief Executive Officer Designate

b)

Β 

Initial notification /Amendment

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Caledonia Investments plc

b)

Β 

LEI

Β 

2138002FX1MYCA5ZZH32

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Β 

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Ordinary 5p shares

Β 

Β 

GB0001639920

b)

Β 

Nature of the transaction

Β 

Β 

Grant of nil-cost options over ordinary 5p shares under (1) the Caledonia Investments 2020 Performance Share Scheme ("PSS") and (2) the Caledonia Investments 2020 Deferred Bonus Plan ("DBP")

Β 

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Β 

Β 

Description

Price(s)

Β 

Volume(s)

Grant of PSS award

Β 

Β£0.00

Β 

18,048

Grant of DBP award

Β 

Β£0.00

3,870

Β 

Β 

d)

Β 

Aggregated information

Β 

- Aggregated volume

Β 

- Price

Β 

Β 

Β 

21,918

Β 

Nil

Β 

e)

Β 

Date of the transaction

Β 

30 May 2022

f)

Place of the transaction

Outside a trading venue

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHBUGDUCSXDGDB
Date   Source Headline
23rd Jun 20224:00 pmRNSAnnual Financial Report
20th Jun 202212:20 pmRNSDirector/PDMR Shareholding
20th Jun 202212:20 pmRNSDirector/PDMR Shareholding
16th Jun 20224:32 pmRNSDirector/PDMR Shareholding
14th Jun 20221:51 pmRNSDirector/PDMR Shareholding
8th Jun 20229:36 amRNSNet Asset Value(s)
6th Jun 20223:33 pmRNSDirector/PDMR Shareholding
31st May 20224:50 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSFinal Results
6th May 20229:02 amRNSNet Asset Value(s)
7th Apr 20227:00 amRNSUnaudited net asset value and portfolio update
4th Apr 202210:10 amRNSDirectorate Change
25th Mar 20224:47 pmRNSDirector/PDMR Shareholding
21st Mar 20223:56 pmRNSDirector/PDMR Shareholding
16th Mar 20222:05 pmRNSDirector/PDMR Shareholding
7th Mar 20227:00 amRNSDirectorate Change
7th Mar 20227:00 amRNSNet Asset Value(s)
28th Feb 20224:59 pmRNSTotal Voting Rights
4th Feb 20224:56 pmRNSTransaction in Own Shares
4th Feb 20229:52 amRNSNet Asset Value(s)
31st Jan 20225:23 pmRNSTotal Voting Rights
28th Jan 20225:25 pmRNSTransaction in Own Shares
7th Jan 202211:40 amRNSUnaudited net asset value and portfolio update
4th Jan 20227:00 amRNSTotal Voting Rights
21st Dec 20214:44 pmRNSDisposal
20th Dec 202110:00 amRNSDirector Declaration
17th Dec 20215:32 pmRNSTransaction in Own Shares
10th Dec 20215:16 pmRNSTransaction in Own Shares
7th Dec 20219:59 amRNSNet Asset Value(s)
30th Nov 20215:30 pmRNSTotal Voting Rights
26th Nov 20214:49 pmRNSTransaction in Own Shares
23rd Nov 20217:00 amRNSBoard Changes
23rd Nov 20217:00 amRNSHalf-year Report
17th Nov 20217:00 amRNSDisposal
4th Nov 202111:22 amRNSNet Asset Value(s)
1st Nov 20219:35 amRNSTotal Voting Rights
29th Oct 20214:49 pmRNSTransaction in Own Shares
15th Oct 20214:57 pmRNSTransaction in Own Shares
8th Oct 20215:16 pmRNSTransaction in Own Shares
7th Oct 202110:48 amRNSNet Asset Value(s)
30th Sep 20215:02 pmRNSTotal Voting Rights
30th Sep 20214:59 pmRNSTransaction in Own Shares
30th Sep 20211:52 pmRNSTransaction in Own Shares
24th Sep 20214:57 pmRNSTransaction in Own Shares
17th Sep 20215:05 pmRNSTransaction in Own Shares
10th Sep 20215:05 pmRNSTransaction in Own Shares
3rd Sep 20215:04 pmRNSTransaction in Own Shares
3rd Sep 202112:12 pmRNSDirector/PDMR Shareholding
31st Aug 20216:00 pmRNSTotal Voting Rights
27th Aug 20215:10 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.